[Research Articles] Preclinical efficacy of the GPER-selective agonist G-1 in mouse models of obesity and diabetes

In conclusion, this work demonstrates that GPER-selective agonism is a viable therapeutic approach against obesity, diabetes, and associated metabolic abnormalities in multiple preclinical male and female models.

Source: Science Translational Medicine - January 28, 2020 Category: Biomedical Science Authors: Sharma, G., Hu, C., Staquicini, D. I., Brigman, J. L., Liu, M., Mauvais-Jarvis, F., Pasqualini, R., Arap, W., Arterburn, J. B., Hathaway, H. J., Prossnitz, E. R. Tags: Research Articles Source Type: research